ResMed (NASDAQ:RMD) Chairman and Chief Executive Officer Michael J. Farrell disposed of 4,991 shares of the company's common stock on March 9, 2026, collecting approximately $1.25 million in proceeds.
The sale was executed at a weighted average price of $251.0322 per share, with individual sale prices spanning from $246.83 to $253.09. At the time of reporting, ResMed shares are trading at $247.11 and the company's market capitalization stands at $35.84 billion.
That same day Farrell also exercised stock options to acquire 4,991 shares at an exercise price of $146.34 per share, representing a total exercise outlay of $730,382. Both the sale and the option exercise were completed under a pre-arranged Rule 10b5-1 trading plan that Farrell adopted on October 31, 2024.
Following these transactions, Farrell's direct ownership of ResMed stock totals 466,223 shares. He also holds an indirect stake of 2,090 shares through the Lisette and Michael Farrell Family Trust.
Context from company results and analyst reactions
ResMed reported solid results for the second quarter of fiscal 2026. The company posted earnings per share of $2.81, above the analysts' consensus of $2.73. Reported revenue of $1.4 billion was in line with expectations.
Analyst responses to the quarterly report included upward adjustments to price targets. RBC Capital increased its price target on ResMed to $314, citing double-digit revenue and earnings growth that marginally exceeded both RBC's own and consensus estimates. KeyBanc Capital Markets raised its target to $302, referencing the company's revenue beat as supportive of its investment thesis. Needham maintained a Hold rating, while highlighting an improvement in organic revenue growth of 8% in the quarter.
These analyst moves reflect a re-evaluation of ResMed's near-term outlook following the quarter's results.
Valuation note
InvestingPro analysis is cited as identifying ResMed as appearing undervalued. The referenced service provides Fair Value estimates and Pro Research Reports covering more than 1,400 U.S. equities.
Summary of the transactions and holdings
- Sale: 4,991 shares sold on March 9, 2026, for a total of $1.25 million.
- Sale pricing: Weighted average sale price $251.0322; individual prices $246.83 to $253.09.
- Exercise: 4,991 options exercised at $146.34 per share for $730,382 total.
- Trading plan: Transactions carried out under a Rule 10b5-1 plan adopted October 31, 2024.
- Post-transaction holdings: 466,223 shares directly owned; 2,090 shares indirectly owned via the Lisette and Michael Farrell Family Trust.
What this covers
This report documents the insider transactions by ResMed's CEO and the company's recent financial results and analyst reactions, preserving the factual details of the trades, option exercise, and subsequent ownership position.